Fourth Circuit rules against Maryland's 340B contract pharmacy law
Issue
The Fourth Circuit vacated a ruling that had upheld Maryland's 340B contract pharmacy law, siding with AbbVie, Novartis and AstraZeneca, as 340B Report covered in April 2026. The Fifth Circuit upheld Mississippi's similar law, so the split may reach the Supreme Court.
H.R. 7391 would shield health centers from the federal rebate pilot but has not left committee.
Key points
- State-level 340B protection laws are losing in federal courts. Two federal bills, H.R. 7391 and S. 5244, would curb the 340B rebate pilot; neither has moved, and neither addresses state contract-pharmacy laws
- 4th/5th Circuit split may head to SCOTUS — major uncertainty for FQHCs without in-house pharmacies
Sources for this story
340B ReportPart of
- 340B drug pricing
State contract-pharmacy laws and the circuit split · Manufacturer restrictions and data demands
Sources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
The newsletter is paused right now. Sign up and you will get it when it starts again.
Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
FQHC Talent. (2026, April 15). Fourth Circuit rules against Maryland's 340B contract pharmacy law. Source: 340B Report. Retrieved November 22, 2026, from https://www.fqhctalent.com/intel/340b-fourth-circuit-maryland-state-law-vacated